The Aim of the Present Study is to Determine Outcome Predictors in Children Who Were Diagnosed as Acute Disseminated Encephalomyelitis (ADEM).
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- This is an observational study: the protocol does not assign a study treatment.
- Who it may be relevant to
- Registry conditions: Acute Disseminated Encephalomyelitis, Encephalomyelitis, Encephalopathy. Basic parameters: 6 months — 18 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Center list to be confirmed — check the primary protocol.
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Outcome Predictors in Children With Acute Disseminated Encephalomyelitis at Assuit University Children Hospital
Overview
The aim of the present study is to determine outcome predictors in children who were diagnosed as acute disseminated encephalomyelitis (ADEM).
Detailed description
Outcome predictors in children with Acute Disseminated Encephalomyelitis
Primary outcome measures
- Proportion of Patients Achieving Complete Recovery Assessed by the Modified Rankin Scale (mRS) [Time frame: 6 months]
Secondary outcome measures (2)
- Incidence of Disease Relapse [Time frame: up to 12 months]
- Incidence of Residual Neurological Deficits [Time frame: up to 12 months]
Eligibility criteria
Inclusion criteria
- Children aged from 6 months old to 18 years.
- Presence of clinical signs of acute encephalopathy with multifocal neurological deficits.
- MRI findings suggestive of demyelinating lesions.
Exclusion criteria
- Pediatric patients diagnosed who were as multiple sclerosis.
- Pediatric patients with clinical signs and radiological findings suggestive of neuromyelitis optica spectrum disorder.
- Pediatric patients with infectious encephalitis.
- Pediatric patients with metabolic or genetic neurological disorders
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Observational model
- Cohort
Study locations
Center list to be confirmed — check the primary protocol.
Publications
- Wang CX. Assessment and Management of Acute Disseminated Encephalomyelitis (ADEM) in the Pediatric Patient. Paediatr Drugs. 2021 May;23(3):213-221. doi: 10.1007/s40272-021-00441-7. Epub 2021 Apr 8. PMID 33830467
- Sechi E, Krecke KN, Messina SA, Buciuc M, Pittock SJ, Chen JJ, Weinshenker BG, Lopez-Chiriboga AS, Lucchinetti CF, Zalewski NL, Tillema JM, Kunchok A, Monaco S, Morris PP, Fryer JP, Nguyen A, Greenwood T, Syc-Mazurek SB, Keegan BM, Flanagan EP. Comparison of MRI Lesion Evolution in Different Central Nervous System Demyelinating Disorders. Neurology. 2021 Sep 14;97(11):e1097-e1109. doi: 10.1212/WNL PMID 34261784
- Pohl D, Alper G, Van Haren K, Kornberg AJ, Lucchinetti CF, Tenembaum S, Belman AL. Acute disseminated encephalomyelitis: Updates on an inflammatory CNS syndrome. Neurology. 2016 Aug 30;87(9 Suppl 2):S38-45. doi: 10.1212/WNL.0000000000002825. PMID 27572859
- Ferenc K, Semik P, Paprocka J. Acute Disseminated Encephalomyelitis (ADEM): Current View into Etiopathogenesis and Clinical Features. Brain Sci. 2026 Feb 9;16(2):201. doi: 10.3390/brainsci16020201. PMID 41750202
Identifiers
NCT: NCT07540182 · ADEM disease